NFE2L2 and metabolic dysfunction-associated steatotic liver disease: Reduced ROS levels by the Nrf2 pathway have been also shown to decrease inflammation in hepatocarcinoma and in non-alcoholic fatty liver disease rat models, since Nrf2 silencing or inhibition of its targets superoxide dismutase and glutathione peroxidase abolished NF-κB inhibition and reduction in inflammatory cytokine secretion induced by the flavonoid hesperetin [51].